Brain nitric oxide production by a proline-rich decapeptide from Bothrops jararaca venom improves baroreflex sensitivity of spontaneously hypertensive rats by Lameu, Claudiana et al.
ORIGINAL ARTICLE
Brain nitric oxide production by a proline-rich
decapeptide from Bothrops jararaca venom
improves baroreflex sensitivity of spontaneously
hypertensive rats
Claudiana Lameu1,2, Vera Pontieri2, Juliano R Guerreiro3, Eduardo F Oliveira2,4, Carlos Alberto da Silva5,
Joyce M Giglio2, Robson L Melo2, Ruy R Campos6, Antonio Carlos Martins de Camargo1,7 and
Henning Ulrich1
Baroreflex sensitivity is disturbed in many people with cardiovascular diseases such as hypertension. Brain deficiency of nitric
oxide (NO), which is synthesized by NO synthase (NOS) in the citrulline–NO cycle (with argininosuccinate synthase (ASS)
activity being the rate-limiting step), contributes to impaired baroreflex. We recently showed that a decapeptide isolated from
Bothrops jararaca snake venom, denoted Bj-PRO-10c, exerts powerful and sustained antihypertensive activity. Bj-PRO-10c
promoted vasodilatation dependent on the positive modulation of ASS activity and NO production in the endothelium, and also
acted on the central nervous system, inducing the release of GABA and glutamate, two important neurotransmitters in the
regulation of autonomic systems. We evaluated baroreflex function using the regression line obtained by the best-fit points of
measured heart rate (HR) and mean arterial pressure (MAP) data from spontaneously hypertensive rats (SHRs) treated with
Bj-PRO-10c. We also investigated molecular mechanisms involved in this effect, both in vitro and in vivo. Bj-PRO-10c
mediated an increase in baroreflex sensitivity and a decrease in MAP and HR. The effects exerted by the peptide include an
increase in the gene expression of endothelial NOS and ASS. Bj-PRO-10c-induced NO production depended on intracellular
calcium fluxes and the activation of a Gi/o-protein-coupled metabotropic receptor. Bj-PRO-10c induced NO production and the
gene expression of ASS and endothelial NOS in the brains of SHRs, thereby improving baroreflex sensitivity. Bj-PRO-10c may
reveal novel approaches for treating diseases with impaired baroreflex function.
Hypertension Research (2010) 33, 1283–1288; doi:10.1038/hr.2010.208
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INTRODUCTION
The gaseous messenger NO is involved mainly in the regulation of
local and systemic vascular resistance, sodium balance and, conse-
quently, blood pressure control,1 but it is also a signaling molecule and
modulator of brain function.2 Recent studies relate NO with central
cardiovascular control through the regulation of the cardiac and
vascular autonomic system via the modulation of the central sites of
cardiovascular autonomic neural integration.3,4
NO is generated in the citrulline–NO cycle by NO synthase (NOS)
using L-arginine as a substrate. Three isoforms of NOS have been
described: calcium-dependent endothelial (eNOS) and neuronal
(nNOS) isoforms and inducible NOS. The expression and activity
of the latter are induced by inflammatory stimuli, independent of the
cytosolic calcium concentration.5
In the citrulline–NO cycle, argininosuccinate synthase (ASS) activ-
ity is rate-limiting with regard to the supply of L-arginine as substrate
for NOS. ASS is an ubiquitous enzyme that is expressed in all tissues,
including the brain.6 This enzyme catalyzes the conjugation reaction
of citrulline with aspartate to generate argininosuccinate, which
in turn is converted by argininosuccinate lyase into fumarate and
L-arginine. L-arginine is cleaved into citrulline and NO, completing
the cycle.6,7
Our group has recently shown that a decapeptide that is rich in
proline residues binds to ASS. This molecule, named Bj-PRO-10c
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or BPP-10c, belongs to a class of peptides isolated from Bothrops
jararaca snake venom. These peptides are products of C-type natriure-
tic peptide precursor protein cleavage in the venom gland and the
brain of the snake8,9 Bj-PRO-10c exerted powerful and sustained
antihypertensive activity10 and vasodilatation depended on the positive
modulation of ASS activity and NO production in the endothelium.11
Changes in mean arterial pressure (MAP) promoted by Bj-PRO-10c
are accompanied by a significant reduction in heart rate (HR),10 rather
than by an increase in HR as would be expected by the discharge of
baroreceptors due to hypotension.12 These results, together with the
observation that about 1% of Bj-PRO-10c administered i.v. to mice is
found in the brains of these animals,13 suggest that this peptide affects
the central nervous system (CNS). Recently, we have shown that
Bj-PRO-10c promotes the release of the neurotransmitters GABA and
glutamate, which are known to participate in the regulation of cardiac
and vascular autonomic systems, thus leading to a decline of MAP
and HR among spontaneously hypertensive rats (SHRs).14 Therefore,
Bj-PRO-10c-induced decreases of MAP and HR could result from
interference of Bj-PRO-10c with the autonomic nervous system,
provoking changes in HR and baroreflex control.15,16
Arterial baroreflex is one of the most important regulatory mechan-
isms in the cardiovascular system. Baroreflex function, expressed as
baroreflex sensitivity, is measured to assess autonomic control. Clinical
evidence has associated arterial baroreflex dysfunction with many
cardiovascular diseases, the sudden death of patients suffering acute
myocardial infarction and mortality in patients with congestive heart
failure.17 Changes in neural–cardiovascular integration due to NO
deficiency may be the main cause of autonomic abnormalities in
several models of experimental hypertension2 as a consequence of
impaired arterial baroreflex.3,18
As a result of augmented ASS activity, an enzyme also expressed in
the CNS,6 and central effects on the control of blood pressure11,14 in
the presence of Bj-PRO-10c, we expected to observe increased NO
production in the brain and improved arterial baroreflex function in
conscious SHRs. Therefore, this study was designed to examine the
effects of Bj-PRO-10c on baroreflex sensitivity in SHRs and to
elucidate involved mechanisms.
METHODS
Synthesis and purification of Bj-PRO-10c
Synthesis of Bj-PRO-10c (oENWPHPQIPP) was performed as detailed else-
where.14,19 Briefly, the synthesis of Bj-PRO-10c was carried out on an auto-
mated PSSM-8 peptide synthesizer (Shimadzu, Chiyoda-ku, Kyoto, Japan) by a
stepwise solid-phase method using N-9-fluorenylmethoxycarbonyl chemistry
(Novabiochem-EMD Chemicals, San Diego, CA, USA). The crude synthetic
peptide was purified by preparative reverse-phase high-performance liquid
chromatography. Buffer elution residues were removed by freeze drying,
followed by confirmation of sequence identity and purity by analytical high-
performance liquid chromatography and MALDI-TOF mass spectrometry
(Amersham Biosciences, Uppsala, Sweden).
Collection of brains of Bj-PRO-10c-treated rats
Male SHRs (270–350 g) from the animal house of the Instituto de Cieˆncias
Biolo´gicas (University of Sa˜o Paulo, Brazil) and normotensive Wistar rats
(270–350 g) from the Butantan Institute were used to obtain the brains for
determination of NO production and mRNA transcription levels. The animals
were kept in a 12:12 light/dark cycle with standard laboratory chow and water
provided ad libitum. All surgical procedures and protocols were in accordance
with Guidelines for Ethical Care of Experimental Animals and had been
previously approved by the Institutional Animal Care and Use Committee of
the Butantan Institute. Cardiovascular parameters of Wistar rats and SHRs
were monitored for 6 h following i.v. injection of 71 nmol kg1 Bj-PRO-10c or
saline as detailed by Ianzer et al.10 Then, animals were anesthetized by injection
of 10% ketamine and 2% xylazine (1:1) in a volume of 50ml followed by
intracardiac perfusion (from the left ventricle and through the right atrium)
with 20 ml of 0.15 M NaCl and 0.01% sodium heparin at a flow rate of
4 ml min1. Brain tissue was immediately removed and frozen to 80 1C until
further use.
Preparation of rat brain cell culture
Whole-brain primary neuronal culture was prepared according to Lameu
et al.14 Cells obtained from dissected brain following removal of pia mater
and blood vessels were dissociated in the presence of trypsin and the cell
suspension was plated onto poly-L-lysine-precoated tissue culture dishes in
Dulbecco’s modified Eagle’s medium containing 10% horse serum (Gibco BRL,
Grand Island, NY, USA), as previously described.20 Following 3 days of culture,
10mM cytosine-arabinoside was added to eliminate cells of non-neuronal
origin.21 Cells were cultured for 10–15 days at 37 1C in a water-saturated
atmosphere containing 5% CO2.
Chemiluminescence assay for the measurement of NO products
NO is a gaseous molecule with an extremely short half-life. It is rapidly
converted into NO-derived products (NOx), such as nitrate, nitrite, nitro-
sothiol, nitrosamines and iron–nitrosyl complexes.22 For the determination of
NOx concentrations in whole-brain homogenates, extra and intracellular media
of rat brain cell culture were analyzed with a chemiluminescence Sievers Nitric
Oxide Analyzer—NOA 280i (GE Analytical Instruments, Boulder, CO, USA),
following the procedure optimized by Feelisch et al.22 Whole brains of SHRs
treated with 71 nmol kg1 Bj-PRO-10c or vehicle control (saline) were homo-
genized in RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Nonidet p-40,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM diethylenetria-
mine pentaacetic acid and 10 mM N-ethylmaleimide). In all experiments, 1 ml of
extracellular cell culture medium was treated with a concentrated solution of
N-ethylmaleimide to give a final concentration of 10 mM. Cells were washed
with phosphate-buffered saline and lysed in RIPA buffer. Cell lysates were
collected and incubated for 30 min on ice and centrifuged for 15 min at 21 000 g
and 4 1C. The collected supernatant contained the intracellular medium.
Immediately after the cell lysis procedure, samples were directly injected into
a vessel containing a saturated solution of vanadium (III) chloride in 1 N HCl at
90 1C for NOx concentration measurements. Under these conditions, all
NOx metabolites were reduced and compared with those of standard nitrate
solutions.22
Real-time PCR
Total RNA was extracted from the brains of SHRs using Trizol (Life Technol-
ogies, Gaithersburg, MD, USA). Every sample was further treated with
Amplification Grade DNase I (Sigma Chemical, Poole, UK). An aliquot of
the sample was used to confirm the absence of any residual DNA that could
generate false-positive results. Reverse transcription reactions for cDNA synth-
esis were performed with a thermal cycler (Applied Biosystems, Foster City, CA,
USA) using the SuperScript III First-Strand synthesis system according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA), in the presence of
primers specific for ASS- , eNOS- and nNOS-coding sequences. The expression
levels of selected mRNAs were measured by real-time PCR using the ABI Step
One Plus Instrument (Applied Biosystems). PCR reactions were performed in
25ml of buffer containing 1ml of cDNA, SYBR Green Master Mix (Applied
Biosystems) and 5 pmol of sequence-specific primer: ASS (forward primer
5¢-TGCACTCTATGAGGACCGCTATC-3¢, reverse primer 5¢-CTAGGCACCTC
TCTCGCCAGGCCT-3¢); eNOS (forward primer 5¢-GACTTTTAAGGAAGT
AGCCAATGCA-3¢, reverse primer 5¢-CCATACAGGATAAGTCGCCTTCAC-3¢);
nNOS (forward primer 5¢-CCAATGTTCACAAAAAACGAGTCT-3¢, reverse
primer 5¢-TCGCCTGGACTTAGGGCTTT-3¢) and glyceraldehyde 3-phosphate
dehydrogenase (forward primer 5¢-TGGCCTCCAAGGAGTAAGAAAC-3¢,
reverse primer 5¢-GGCCTCTCTCTTCCTCTCAGTATC-3¢). Thermal cycling
conditions consisted of a preincubation step for 2 min at 50 1C, then denatura-
tion for 10 min at 95 1C followed by 40 cycles of denaturation for 15 s at 95 1C
and annealing/extension for 1 min at 60 1C. The comparative 2DDCT method
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was used for the relative quantification of gene expression as described
previously.23
Baroreceptor reflex assay
Normotensive Wistar rats and SHRs (270–350 g) were anesthetized with
0.05 ml of 10% ketamine and 2% xylazine (1:1), and catheters (TYGON
Flexible Plastic Tubing, Saint-Gobain Performance Plastics Corporation, New
Haven, CT, USA) were inserted into the femoral artery and vein for cardio-
vascular monitoring and drug administration. The catheters were tunneled
subcutaneously to the back of neck, where they were fixed. Following recovery
from anesthesia for 1 day, both MAP and HR were recorded continuously in
freely moving rats using BIOPAC Systems instrumentation (BIOPAC Systems,
Goleta, CA, USA). After recording the basal values of MAP and HR, control
measurements of MAP and HR were followed by repeated stimulation of
baroreceptors with 0.1 ml bolus injections of graded doses of phenylephrine
(0.1–6.4mg kg1) and sodium nitroprusside (0.2–12.8mg kg1) into the femoral
vein. Phenylephrine and sodium nitroprusside injections were given in a
random order, and subsequent stimulations were not applied until the recorded
parameters had returned to preinjection levels. The peak increase or decrease in
MAP after each injected dose of phenylephrine and sodium nitroprusside was
correlated with the peak reflex change in HR. Average values obtained during a
fixed time interval were used to quantify reflex changes. Baroreflex sensitivity
was analyzed by the regression line obtained by best-fit points to measured HR
(bpm) and MAP (mm Hg) data.24
Statistical analysis
Statistical analysis was conducted using one-way ANOVA, employing the
GraphPad3 software. Differences were considered significant when Po0.05.
RESULTS
Bj-PRO-10c-induced NO production in the brains of SHRs
The Bj-PRO-10c action on NO production in rat brains was
determined by measuring NO metabolites (NOx¼nitrate, nitrite,
nitrosothiol, nitrosamines and iron-nitrosyl complexes) in primary
brain cell cultures of SHRs and whole brains of normo- and hyper-
tensive rats in the presence and absence of the peptide. The concen-
tration of NOx in the brains of SHRs was 93.5±18.5mM following 6 h
of treatment with 71 nmol kg1 Bj-PRO-10c, which was 34% higher
than the NOx content of control rats (69.3±12.1mM). In the brains
of normotensive rats, the NOx content did not change following
treatment with the same concentration of Bj-PRO-10c (Figure 1).
Bj-PRO-10c also led to an increase in NOx concentration in cell
culture from 0.38±0.01mM to 1.04±0.04mM (Figure 2). For the
elucidation of Bj-PRO-10c-mediated signal transduction, cells were
exposed for 24 h to 1mM Bj-PRO-10c in the absence or presence
of 100 ng ml1 pertussis toxin (an inhibitor of Gi/o-protein-coupled
metabotropic receptor activation), 10 mM ethylene glycol tetraacetic
acid (EGTA; to chelate extracellular calcium), or 200 ng ml1 thapsi-
gargin (an inhibitor of endoplasmic reticulum Ca2+-ATPase).25
Bj-PRO-10c-evoked NOx production was reduced by thapsigargin
and EGTA to 0.39±0.01 and 0.59±0.09mM, respectively. As a result
of these studies, both calcium influx and the mobilization of intra-
cellular calcium stores contributed to Bj-PRO-10c-induced signaling
and NO production. Pertussis toxin also interfered with NO produc-
tion, suggesting the participation of a Gi/o-protein-coupled metabo-
tropic receptor in the Bj-PRO-10c-induced signaling pathway
(Figure 2).
Regulation of ASS and eNOS gene expression in SHR brain
by Bj-PRO-10c
We have analyzed the gene expression of the enzymes ASS, eNOS and
nNOS, which are known to be involved in NO synthesis. Real-time
PCR revealed that Bj-PRO-10c mediated 2.2±0.8- and 1.9±0.34-fold
increases in ASS and eNOS mRNA transcription levels, respectively,
when compared with the gene expression rates of vehicle-treated
control animals. However, nNOS expression in the brains of
Bj-PRO-10c-treated SHRs was not significantly different from that
observed in the control group (Figure 3).
Figure 1 NO concentration in the brain of normotensive (Wistar) and
hypertensive rats (SHRs) treated with Bj-PRO-10c. Conscious rats (n¼4)
were treated with 71 nmol kg1 Bj-PRO-10c or saline i.v. After 6 h of
treatment, animals were anesthetized and then the brain was removed and
homogenized in RIPA buffer. The homogenate was used to measure the NO
concentration by using a chemiluminescence assay. The data are presented
as mean values±s.e. compared with the vehicle-treated rats, for a period
up to 6 h. *Po0.05.
Figure 2 Bj-PRO-10c induced NO metabolites production in neuronal cells.
Neuronal cells obtained from postnatal (1-day-old) SHRs were seeded into
poly-D-lysine-coated Petri dishes in appropriate medium and incubated for
24 h. Afterwards, cells were kept for 24h in serum-free medium containing
1mM of Bj-PRO-10c. The medium was collected and the cells were lysed
with RIPA buffer for measuring NO products in extracellular and intracellular
media by a chemiluminescence assay. Bj-PRO-10c-induced NO production
was also determined in the presence of 100 ngml1 pertussis toxin (PTX),
10 mM EGTA or 200ngml1 thapsigargin. NO concentration was expressed
as mean values±s.e. of six experiments. ***Po0.001 compared with basal
NO levels; ##Po0.01; ###Po0.001 compared with NO production in the
presence of Bj-PRO-10c.
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Bj-PRO-10c improves baroreflex sensitivity of SHRs
The baroreceptor reflex activities of conscious normotensive
Wistar rats and SHRs were determined immediately, 1 or 4 h after
the i.v. administration of 71 nmol kg1 Bj-PRO-10c. The baroreflex
sensitivity of SHRs analyzed by DHR/DMAP indexes (b¼best-fit
slope) for bradycardia and tachycardia were 1.7±0.3 and 0.5±
0.1 bpm (mm Hg)1, and those of normotensive rats were 4.8±0.4
and 1.6±0.2 bpm (mm Hg)1, respectively. These data are in agree-
ment with a previous study by Krieger and co-workers demonstrating
that SHRs have impaired sensitivity with regard to baroreflex control
of HR.26 After Bj-PRO-10c injection, the baroreflex sensitivity of
normotensive rats for the control of HR was unchanged (Figure 4a);
however, baroreflex sensitivity increased among SHRs. The im-
provement of baroreflex sensitivity occurred only during periods of
decreasing MAP (Table 1). One after Bj-PRO-10c injection, baro-
reflex sensitivity increased to 0.7±0.1 bpm (mm Hg)1. After 4 h,
the elevation of baroreflex sensitivity was even higher, reaching
0.9±0.1 bpm (mm Hg)1. No change was observed in tachycardic
baroreflex following Bj-PRO-10c application (Figure 4b).
DISCUSSION
Our group, attempting to elucidate molecular mechanism of the
antihypertensive activity of Bj-PRO-10c, identified ASS as a target
for this peptide.11 ASS is the rate-limiting enzyme of the citrulline–NO
cycle that regulates the supply of L-arginine as a substrate for NOS.6
We showed that Bj-PRO-10c administration results in augmented NO
production in SHR brain tissues as well as in primary cultures of
postnatal SHR brain neurons. Bj-PRO-10c-induced NO production in
neuronal cells was abolished by pretreatment of cells with ASS and
NOS inhibitors (data not shown). These results were in agreement
with those obtained in endothelial cells.11 The results of the latter
experiments suggested that Bj-PRO-10c-induced NO production
involved calcium fluxes because both calcium signaling and NO
production were affected by pretreatment with thapsigargin, EGTA
and pertussis toxin. These results are in agreement with previous
research.14
NO has been attributed to various functions, including non-
cholinergic and non-adrenergic smooth muscle relaxation, the
reduction of arterial pressure and signal transmission in the CNS.2
NO-mediated actions in the CNS include central vascular regulation27
and the baroreflex control of HR.18 Antihypertensive activity, based on
the facilitated release of GABA and glutamate in the CNS, and NO
production are suggested to result in diminished transmission of
sympathetic tone to the periphery.27 However, no Bj-PRO-10c-
induced changes of the sympathetic renal activity of SHRs were
observed under anesthesia, and MAP of these animals also remained
unchanged (data not shown). It is known that some anesthetics, such
as pentobarbital, block the sympathetic nervous system28 and subse-
quently prevent changes in blood pressure, thereby explaining
Figure 3 Regulation of ASS, eNOS and nNOS expression in SHR brain.
SHRs were anesthetized 6 h after endovenous injection of 71 nmol kg1
Bj-PRO-10c and brains were removed for RNA extraction. Gene expression
changes in SHR treated with Bj-PRO-10c brain was analyzed by quantitative
real-time PCR and normalized using glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) gene expression as internal control. The obtained data were
compared with gene expression levels of vehicle-treated SHRs. *Po0.05;
***Po0.001 (n¼4).
Figure 4 Baroreflex control of heart rate (HR) in rats. Average baroreflex
linear curves obtained by means changes in heart rate (oHR) due to
induced changes in mean arterial pressure (MAP) (oMAP) in normotensive
(a) and spontaneously hypertensive (b) rats before (control), and 1 and
4 h after endovenous administration of 71 nmol kg1 Bj-PRO-10c. Lines
represent linear regression fitting of changes in HR and MAP. The slope of
linear regressions (b) was used to determine the gain of the baroreflex
sensitivity. *Po0.05 and ***Po0.001 compared with control (absence of
Bj-PRO-10c) (b¼best-fit slope).
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the inefficiency of Bj-PRO-10c action under these experimental
conditions. In addition, baroreflex sensitivity can be used as an
index of autonomic control; thus, this observation provides further
evidence for the participation of the sympathetic nervous system in
Bj-PRO-10c-mediated effects.
Recent evidence suggests that changes in arterial baroreflex control
and the autonomous nervous system are involved in the development
and maintenance of hypertension.29–31 In a classic study carried out
in the 1960’s, Bristow et al.32 reported for the first time that the
baroreflex control of HR in patients with hypertension was signifi-
cantly lower than that of normotensive individuals. Herein, we have
observed that baroreflex sensitivity in normotensive rats is much
higher than in SHRs, which supports the previous study.26 Interven-
tionist attitudes that seek improvement in arterial baroreflex sensitiv-
ity are considered to be new strategies for the management of
cardiovascular diseases, especially hypertension.26,33
Recently, we published a study showing that Bj-PRO-10c mediated
CNS actions to decrease arterial pressure and HR in SHRs. Bj-PRO-
10c-induced intracellular calcium signaling involved the activation of
G-protein-coupled receptors and the release of neurotransmitters such
as GABA and glutamate.14 Both GABA and glutamate participate in
the regulation of vasodilatation through the reduction of sympathetic
activity and baroreflex sensitivity control.34 Herein, we show that the
i.v. application of Bj-PRO-10c resulted in augmented baroreflex
sensitivity. We observed that baroreflex sensitivity was most increased
after 4 h of treatment with Bj-PRO-10c. However, the effects exerted
by this peptide were less pronounced at 1 h after exposure to Bj-PRO-
10c. These observations may explain the moderate reduction in
arterial pressure that occurs after the first hour and the higher and
prolonged rise in arterial pressure that occurs 3 h after the i.v. injection
of the peptide.10 Furthermore, no effect on baroreflex sensitivity was
observed in normotensive rats, just as significant changes in MAP and
HR of normotensive rats were not previously found after administra-
tion of Bj-PRO-10c10 (Table 1).
Baroreflex function, which has an important role in regulating
blood pressure, in both the short and long term, is influenced by
genetic factors.35 Xing-Sheng et al.31 concluded from human genetic
studies that polymorphism of the eNOS gene results in reduced eNOS
activity, indicating a depressant effect of eNOS-generated NO on
baroreflex sensitivity. Based on the observation that Bj-PRO-10c
induced production of NO in neuronal cells from postnatal whole-
SHR-brain cell culture, we analyzed the gene expression levels of ASS,
eNOS and nNOS, which are known to be involved in NO synthesis.
Bj-PRO-10c treatment induced an increase in ASS gene expression;
ASS is an essential enzyme in the citrulline–NO cycle that promotes
the production of L-arginine as a natural, unique substrate for NOS.
A previous study showed that Bj-PRO-10c potentiated ASS activity
in vitro and in vivo, resulting in increased intracellular L-arginine
concentration.11 Endogenous L-arginine synthesis, as part of the
citrulline–NO cycle, is crucial for NO production because most of
the ingested L-arginine is degraded by liver arginase.36 ASS is widely
distributed throughout the brain and interneurons, and it has possible
neuromodulatory effects;37 however, this is the first time that evidence
has been provided for the involvement of ASS in the central control of
blood pressure.
In contrast, nNOS was not differentially expressed in Bj-PRO-10c-
treated SHR brains when compared with vehicle-treated animals.
However, the gene expression levels of eNOS, similar to those of
ASS, were also augmented in the brains of animals treated with the
peptide. Our data agree with the results obtained by Kishi et al.38
showing that the overexpression of eNOS in the rostral ventrolateral
medulla and the nucleus of the solitary tract of hypertensive and
Wistar rats results in reduced systolic arterial pressure and reduced
HR. However, the decrease in arterial pressure was more pronounced
in SHRs when compared with Wistar rats with normal blood
pressure.38 It has been suggested that the development of hypertension
in SHRs involves abnormalities in the citrulline–NO cycle.39 Although
high concentrations of nNOS are present in the CNS and principally
in nucleus of the solitary tract and rostral ventrolateral medulla, its
expression levels do not differ between SHRs and rats with normal
arterial pressures.39 This observation suggests that there are other
compensatory mechanisms for the reduction of arterial pressure that
do not involve nNOS activity. The reduction of blood pressure
following eNOS activation may be due to decreased sympathetic
nerve activity.39
In summary, the increased expression of eNOS led to augmented
baroreflex sensitivity in the brains of hypertensive rats and reduced
MAP and HR,40 as observed in our studies following Bj-PRO-10c
administration. These effects result from increased eNOS expres-
sion and appear to depend on NO-induced liberation of GABA.38
In support of such a mechanism, Bj-PRO-10c also provoked GABA
release in brain cell culture14 in addition to diminishing MAP and
HR and increasing baroreflex sensitivity, as shown in the present
study.
We have described a new mechanism of action for Bj-PRO-10c
previously known for its strong angiotensin I converting enzyme
inhibitor properties. Through this mechanism, Bj-PRO-10c induces
NO production which has key roles in the baroreflex control mechan-
ism. Most importantly, the dose of Bj-PRO-10c required to effectively
increase baroreflex sensitivity and induce changes in NO production
and mRNA transcription levels is not sufficient for angiotensin I
converting enzyme inhibition in vivo.10
The fact that Bj-PRO-10c interacts with ASS, a target that is
untapped by the pharmaceutical industry, and modulates gene expres-
sion of key enzymes in NO production opens avenues for its use
as a structural model for the development of novel pharmacological
agents for treating diseases characterized by impaired baroreflex
function.
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Table 1 Effects of Bj-PRO-10c (71nmol kg1) on MAP, HR and










Control 120 347 4.8±0.4 1.6±0.2
1 h 117 326 4.3±0.4 1.7±0.1
4 h 118 363 4.8±1.2 1.9±0.1
Hypertensive
Control 191 404 1.7±0.3 0.5±0.1
1 h 179 351 1.7±0.4 0.7±0.1*
4 h 163 340 1.5±0.2 0.9±0.1***
Abbreviations: HR, heart rate; MAP, mean arterial pressure; SHR, spontaneously hypertensive rat.
*Po0.05 and ***Po0.001 compared with control (absence of Bj-PRO-10c).
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